 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Pharmacotherapy Faculty, Florida Hospital Family Practice Residency, Orlando, FL
Campus Director/Clinical Assistant Professor, University of Florida College of Pharmacy, Orlando Campus, Apopka, FL
Reprints: Dr. Miller, Florida Hospital Family Practice Residency, 7975 Lake Underhill Rd., Suite 200, Orlando, FL 32822-8204, fax 407/303-6839, Shannon.miller{at}flhosp.org
OBJECTIVE: To review the pharmacology, pharmacokinetics, safety, and efficacy of sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibitor in the management of type 2 diabetes mellitus.
DATA SOURCES: A MEDLINE search (1966-February 2006) was conducted for English-language articles using the terms dipeptidyl peptidase IV inhibitor, incretin, MK-0431, and sitagliptin. Abstracts from the American Diabetes Association annual meetings in 2004 and 2005 were included as sources of data.
STUDY SELECTION AND DATA EXTRACTION: Articles pertaining to the pharmacology of sitagliptin, its pharmacokinetics, safety and efficacy were reviewed.
DATA SYNTHESIS: Sitagliptin is a potent, competitive, reversible inhibitor of the DPP-IV enzyme. It is eliminated renally, with a terminal half-life of 11.8-14.4 hours. In Phase II clinical trials, sitagliptin was found to be superior to placebo for the treatment of type 2 diabetes mellitus. Results of a small trial comparing sitagliptin with glipizide indicate that both treatments are comparable. The efficacy of sitagliptin has also been demonstrated when used as adjunctive therapy with metformin. Few adverse effects have been reported. Weight gain and hypoglycemia have not been seen with sitagliptin therapy.
CONCLUSIONS: Based on its unique mechanism of action, sitagliptin will provide practitioners with an additional tool in the treatment of diabetes. Review of the literature to date implies sitagliptin may be effective as monotherapy in type 2 diabetes. In addition, existing evidence supports the use of sitagliptin as adjunct therapy to sulfonylureas and metformin. Another advantage of sitagliptin use is that it appears to be free from the adverse effects of weight gain and hypoglycemia that are associated with currently available treatments.
Key Words: dipeptidyl peptidase IV inhibitor, incretin, MK-0431, sitagliptin
Published Online, July 25, 2006. www.theannals.com, DOI 10.1345/aph.1G665
THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-06-018-H01
This article has been cited by other articles:
|
|
 |
|
  E. L. St. Onge, S. A. Miller, and J. R. Taylor Novel Approaches to the Treatment of Type 2 Diabetes Journal of Pharmacy Practice, June 1, 2009; 22(3): 320 - 332. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Focosi, R. E. Kast, S. Galimberti, and M. Petrini Conditioning response to granulocyte colony-stimulating factor via the dipeptidyl peptidase IV-adenosine deaminase complex J. Leukoc. Biol., August 1, 2008; 84(2): 331 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Forssmann, C. Stoetzer, M. Stephan, C. Kruschinski, T. Skripuletz, J. Schade, A. Schmiedl, R. Pabst, L. Wagner, T. Hoffmann, et al. Inhibition of CD26/Dipeptidyl Peptidase IV Enhances CCL11/Eotaxin-Mediated Recruitment of Eosinophils In Vivo J. Immunol., July 15, 2008; 181(2): 1120 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Bloom and M. F. Crutchlow New-Onset Diabetes Mellitus in the Kidney Recipient: Diagnosis and Management Strategies Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(Supplement_2): S38 - S48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Crutchlow and R. D. Bloom Transplant-Associated Hyperglycemia: A New Look at an Old Problem Clin. J. Am. Soc. Nephrol., March 1, 2007; 2(2): 343 - 355. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
